Abpro Holdings and Celltrion announced submission of an IND to the U.S. FDA for ABP‑102 (CT‑P72), a HER2×CD3 T‑cell engager designed for HER2‑positive solid tumors. Pending clearance, a Phase I trial is expected to start in the first half of next year to evaluate safety, dosing and preliminary activity. ABP‑102 is a bispecific designed to recruit T cells to tumor cells expressing HER2; the partners cited preclinical potency and manufacturability as rationales for clinical advancement. The IND filing marks another entrant into the crowded bispecific space aimed at solid tumors, which has struggled with on‑target off‑tumor toxicity in earlier programs. Investigators and sponsors will focus on first‑in‑human safety, on‑target selectivity and patient selection strategies to mitigate normal‑tissue risk while seeking evidence of antitumor activity.